NCT05872022

A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy

Wegovy® (Semaglutide 2.4 mg) Pregnancy Registry Study: A Prospective Cohort Study to Investigate Safety Outcomes of Exposure to Wegovy During Pregnancy

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 728 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Female
• Age: 15 Years – 50 Years
• Healthy volunteers: —

Summary

This is an observational, prospective Wegovy (semaglutide 2.4 milligram \[mg\]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition with outcomes in an internal comparison cohort of pregnant women with obesity or overweight with at least one weight related comorbid condition at conception and who are not exposed to Wegovy or other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy. Infant outcomes will be assessed throughout the infant's first year of life, with active data collection by the registry occurring at 4 and 12 months after delivery.

Conditions

• Pregnancy
• Obesity
• Overweight

Interventions

Type	Name	Description
OTHER	No Intervention	This is a non-interventional study, therefore no intervention is used.

Timeline

• Start date: 2023-07-05
• Primary completion: 2032-10-31
• Completion: 2032-12-30
• First posted: 2023-05-23
• Last updated: 2026-01-14

Locations

3 sites across 3 countries: United States, Spain, United Kingdom